AAP
BCYC

Arax Advisory Partners’s Bicycle Therapeutics BCYC Stock Holding History

Arax Advisory Partners’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-29
Closed -$205 – 3831
2025
Q4 		$205 Buy
+29
New +$214 ﹤0.01% 3713

Other funds holding BCYC

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
GP
GSK plc London $599M AUM
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Arax Advisory Partners's BCYC Position: Q1 2026 in Review

Arax Advisory Partners sold out of Bicycle Therapeutics (BCYC) in Q1 2026, closing a stake of 29 shares — an estimated $205 sold.

Arax Advisory Partners first reported a position in BCYC in Q4 2025 and held it in 1 quarter. The position peaked at $205 in Q4 2025. 98 funds tracked by Wall St. Rank hold BCYC as of Q1 2026.

  • Arax Advisory Partners reported no remaining Bicycle Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Arax Advisory Partners sold 29 Bicycle Therapeutics shares in Q1 2026, an estimated $205.
  • Arax Advisory Partners first reported a position in Bicycle Therapeutics in Q4 2025 and held it in 1 quarter.
  • Arax Advisory Partners's Bicycle Therapeutics position peaked at $205 in Q4 2025.
  • 98 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.